A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer responds to initial hormonal (castration) therapy. This type of prostate cancer is called metastatic, castrate-resistant prostate cancer.

Key facts

Study ID

NCT01834651

Run by

Edwin Posadas, MD

People needed

17

Starts

2013-04-30

Expected to finish

2016-07-18

Last updated by the study team

2017-09-27

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.